Cargando…

Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL

The BCR-ABL kinase inhibitor, imatinib mesylate, is the front-line treatment for chronic myeloid leukemia, but the emergence of imatinib resistance has led to the search for alternative drug treatments. There is a pressing need, therefore, to develop and test novel drugs. Natural products including...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Chun-Guang, Zhong, Liang, Liu, Yong-Li, Shi, Xue-Jun, Shi, Long-Qin, Zeng, Li, Liu, Bei-Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739139/ https://www.ncbi.nlm.nih.gov/pubmed/27698265 http://dx.doi.org/10.1177/1534735416664784

Ejemplares similares

Regulation of hTERT by BCR-ABL at multiple levels in K562 cells
por: Chai, Juin Hsien, et al.
Publicado: (2011)

Persistence of chronic myelocytic leukemia despite deletion of rearranged bcr/c-abl sequences in blast crisis
Publicado: (1986)

bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia
Publicado: (1985)

miRNA143 Induces K562 Cell Apoptosis Through Downregulating BCR-ABL
por: Liang, Bing, et al.
Publicado: (2016)

Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells
por: Dong, Yan, et al.
Publicado: (2017)

ND-09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR-ABL signaling
por: Liu, Yan-Hong, et al.
Publicado: (2021)

Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells
por: Al-Rawashde, Futoon Abedrabbu, et al.
Publicado: (2021)

[Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling
por: Liu, Yan-Hong, et al.
Publicado: (2023)

Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl(+) K562 and Jak2(V617F)(+) HEL Leukemia Cells
por: Weber, Axel, et al.
Publicado: (2015)

Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells
por: Lu, Xuxiu, et al.
Publicado: (2019)

Transferred BCR/ABL DNA from K562 Extracellular Vesicles Causes Chronic Myeloid Leukemia in Immunodeficient Mice
por: Cai, Jin, et al.
Publicado: (2014)

Synergistic cytotoxicity effect of the combination of chitosan nanoencapsulated imatinib mesylate and quercetin in BCR-ABL positive K562 cells
por: Kamyabi, Rohollah, et al.
Publicado: (2023)

8-Hydroxydaidzein, an Isoflavone from Fermented Soybean, Induces Autophagy, Apoptosis, Differentiation, and Degradation of Oncoprotein BCR-ABL in K562 Cells
por: Wu, Pei-Shan, et al.
Publicado: (2020)

EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway
por: Huang, Rui, et al.
Publicado: (2018)

BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014)

S6K1 determines the metabolic requirements for BCR-ABL survival
por: Barger, Jennifer F., et al.
Publicado: (2012)

Pten regulates homeostasis and inflammation-induced migration of myelocytes in zebrafish
por: Dong, Zhi-Wei, et al.
Publicado: (2014)

In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells
por: Zhou, Qianxiang, et al.
Publicado: (2016)

PTEN and rapamycin inhibiting the growth of K562 cells through regulating mTOR signaling pathway
por: Cheng, Zhi Y, et al.
Publicado: (2008)

Deletion of ABL/BCR on der(9) associated with severe basophilia
por: Vaidya, Shantashri, et al.
Publicado: (2011)

Acceleration of Bcr-Abl(+) leukemia induced by deletion of JAK2
por: Grundschober, E, et al.
Publicado: (2014)

Atorvastatin Exerts Antileukemia Activity via Inhibiting Mevalonate-YAP Axis in K562 and HL60 Cells
por: Zhang, Lei, et al.
Publicado: (2019)

Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant
por: Salomoni, Paolo, et al.
Publicado: (1998)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

靶向抑制miRNA-21对K562细胞增殖及PTEN-PI3K/AKT通路的影响
Publicado: (2016)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes
por: Ohyashiki, Kazuma, et al.
Publicado: (1990)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms
por: Lan, Xiaoying, et al.
Publicado: (2016)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Acute Myelocytic Leukæmia
por: Elder, William, et al.
Publicado: (1904)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia
Publicado: (2019)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

TSPAN7 Exerts Anti-Tumor Effects in Bladder Cancer Through the PTEN/PI3K/AKT Pathway
por: Yu, Xi, et al.
Publicado: (2021)

Overexpression of GATA4 enhances the antiapoptotic effect of exosomes secreted from cardiac colony-forming unit fibroblasts via miRNA221-mediated targeting of the PTEN/PI3K/AKT signaling pathway
por: Hao, Chunshu, et al.
Publicado: (2020)

Entire ABL1 Gene Deletion Without BCR/ABL1 Rearrangement in a Female Patient with B-Cell Precursor Acute Lymphoblastic Leukemia
por: Jiang, Yijing, et al.
Publicado: (2020)

Characterization of an Etoposide‐resistant Human K562 Cell Line, K/eto
por: Sugawara, Isamu, et al.
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_m7r95m0ngjr2gfhb0mdl06n7td